[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, 2021, 71(3), 209-249.
[2] Gupta, S. C., Sung, B., Prasad, S., Webb, L. J. and Aggarwal, B. B., Cancer drug discovery by repurposing: teaching new tricks to old dogs, Trends Pharmacol Sci, 2013, 34(9), 508-517.
[3] Xue, H., Li, J., Xie, H. and Wang, Y., Review of Drug Repositioning Approaches and Resources, Int J Biol Sci, 2018, 14(10), 1232-1244.
[4] Zhao, Y., Chen, X., Chen, J. and Qi, X., Decoding Connectivity Map-based drug repurposing for oncotherapy, Brief Bioinform, 2023, 24(3), .
[5] Ashburn, T. T. and Thor, K. B., Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov, 2004, 3(8), 673-683.
[6] Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S. and Schutjens, M. H., Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov Today, 2015, 20(8), 1027-1034.
[7] Lo, Y. C., Rensi, S. E., Torng, W. and Altman, R. B., Machine learning in chemoinformatics and drug discovery, Drug Discov Today, 2018, 23(8), 1538-1546.
[8] Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H. and Yuan, S., Advancing Drug Discovery via Artificial Intelligence, Trends Pharmacol Sci, 2019, 40(8), 592-604.
[9] Heikamp, K. and Bajorath, J., Support vector machines for drug discovery, Expert Opin Drug Discov, 2014, 9(1), 93-104.
[10] Jarada, T. N., Rokne, J. G. and Alhajj, R., A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions, J Cheminform, 2020, 12(1), 46.
[11] Badkas, A., De Landtsheer, S. and Sauter, T., Topological network measures for drug repositioning, Brief Bioinform, 2021, 22(4), .
[12] Fakhraei, S., Huang, B., Raschid, L. and Getoor, L., Network-Based Drug-Target Interaction Prediction with Probabilistic Soft Logic, IEEE/ACM Trans Comput Biol Bioinform, 2014, 11(5), 775-787.
[13] Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L. and Zeng, J., A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information, Nat Commun, 2017, 8(1), 573.
[14] Pantziarka, P., Verbaanderd, C., Huys, I., Bouche, G. and Meheus, L., Repurposing drugs in oncology: From candidate selection to clinical adoption, Semin Cancer Biol, 2021, 68, 186-191.
[15] Brown, A. S. and Patel, C. J., MeSHDD: Literature-based drug-drug similarity for drug repositioning, J Am Med Inform Assoc, 2017, 24(3), 614-618.
[16] Zhu, Q., Tao, C., Shen, F. and Chute, C. G., Exploring the pharmacogenomics knowledge base (PharmGKB) for repositioning breast cancer drugs by leveraging Web ontology language (OWL) and cheminformatics approaches, Pac Symp Biocomput, 2014, 172-182.
[17] Mullen, J., Cockell, S. J., Woollard, P. and Wipat, A., An Integrated Data Driven Approach to Drug Repositioning Using Gene-Disease Associations, PLoS One, 2016, 11(5), e0155811.
[18] Chen, B., Ding, Y. and Wild, D. J., Assessing drug target association using semantic linked data, PLoS Comput Biol, 2012, 8(7), e1002574.
[19] Kitsiranuwat, S., Suratanee, A. and Plaimas, K., Integration of various protein similarities using random forest technique to infer augmented drug-protein matrix for enhancing drug-disease association prediction, Sci Prog, 2022, 105(3), 368504221109215.
[20] Choudhury, C., Arul Murugan, N. and Priyakumar, U. D., Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods, Drug Discov Today, 2022, 27(7), 1847-1861.
[21] Kitchen, D. B., Decornez, H., Furr, J. R. and Bajorath, J., Docking and scoring in virtual screening for drug discovery: methods and applications, Nat Rev Drug Discov, 2004, 3(11), 935-949.
[22] Yuan, C., Wang, M. H., Wang, F., Chen, P. Y., Ke, X. G., Yu, B., Yang, Y. F., You, P. T. and Wu, H. Z., Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer, Life Sci, 2021, 270, 119105.
[23] Musa, A., Ghoraie, L. S., Zhang, S. D., Glazko, G., Yli-Harja, O., Dehmer, M., Haibe-Kains, B. and Emmert-Streib, F., A review of connectivity map and computational approaches in pharmacogenomics, Brief Bioinform, 2017, 18(5), 903.
[24] Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J. P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S. and Golub, T. R., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease, Science, 2006, 313(5795), 1929-1935.
[25] Lamb, J., The Connectivity Map: a new tool for biomedical research, Nat Rev Cancer, 2007, 7(1), 54-60.
[26] Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., Lahr, D. L., Hirschman, J. E., Liu, Z., Donahue, M., Julian, B., Khan, M., Wadden, D., Smith, I. C., Lam, D., Liberzon, A., Toder, C., Bagul, M., Orzechowski, M., Enache, O. M., Piccioni, F., Johnson, S. A., Lyons, N. J., Berger, A. H., Shamji, A. F., Brooks, A. N., Vrcic, A., Flynn, C., Rosains, J., Takeda, D. Y., Hu, R., Davison, D., Lamb, J., Ardlie, K., Hogstrom, L., Greenside, P., Gray, N. S., Clemons, P. A., Silver, S., Wu, X., Zhao, W. N., Read-Button, W., Wu, X., Haggarty, S. J., Ronco, L. V., Boehm, J. S., Schreiber, S. L., Doench, J. G., Bittker, J. A., Root, D. E., Wong, B. and Golub, T. R., A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles, Cell, 2017, 171(6), 1437-1452.e1417.
[27] Keenan, A. B., Jenkins, S. L., Jagodnik, K. M., Koplev, S., He, E., Torre, D., Wang, Z., Dohlman, A. B., Silverstein, M. C., Lachmann, A., Kuleshov, M. V., Ma'ayan, A., Stathias, V., Terryn, R., Cooper, D., Forlin, M., Koleti, A., Vidovic, D., Chung, C., Schürer, S. C., Vasiliauskas, J., Pilarczyk, M., Shamsaei, B., Fazel, M., Ren, Y., Niu, W., Clark, N. A., White, S., Mahi, N., Zhang, L., Kouril, M., Reichard, J. F., Sivaganesan, S., Medvedovic, M., Meller, J., Koch, R. J., Birtwistle, M. R., Iyengar, R., Sobie, E. A., Azeloglu, E. U., Kaye, J., Osterloh, J., Haston, K., Kalra, J., Finkbiener, S., Li, J., Milani, P., Adam, M., Escalante-Chong, R., Sachs, K., Lenail, A., Ramamoorthy, D., Fraenkel, E., Daigle, G., Hussain, U., Coye, A., Rothstein, J., Sareen, D., Ornelas, L., Banuelos, M., Mandefro, B., Ho, R., Svendsen, C. N., Lim, R. G., Stocksdale, J., Casale, M. S., Thompson, T. G., Wu, J., Thompson, L. M., Dardov, V., Venkatraman, V., Matlock, A., Van Eyk, J. E., Jaffe, J. D., Papanastasiou, M., Subramanian, A., Golub, T. R., Erickson, S. D., Fallahi-Sichani, M., Hafner, M., Gray, N. S., Lin, J. R., Mills, C. E., Muhlich, J. L., Niepel, M., Shamu, C. E., Williams, E. H., Wrobel, D., Sorger, P. K., Heiser, L. M., Gray, J. W., Korkola, J. E., Mills, G. B., LaBarge, M., Feiler, H. S., Dane, M. A., Bucher, E., Nederlof, M., Sudar, D., Gross, S., Kilburn, D. F., Smith, R., Devlin, K., Margolis, R., Derr, L., Lee, A. and Pillai, A., The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations, Cell Syst, 2018, 6(1), 13-24.
[28] Duan, Q., Flynn, C., Niepel, M., Hafner, M., Muhlich, J. L., Fernandez, N. F., Rouillard, A. D., Tan, C. M., Chen, E. Y., Golub, T. R., Sorger, P. K., Subramanian, A. and Ma'ayan, A., LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures, Nucleic Acids Res, 2014, 42(Web Server issue), W449-460.
[29] Williams, G., A searchable cross-platform gene expression database reveals connections between drug treatments and disease, BMC Genomics, 2012, 13, 12.
[30] Iorio, F., Shrestha, R. L., Levin, N., Boilot, V., Garnett, M. J., Saez-Rodriguez, J. and Draviam, V. M., A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions, PLoS One, 2015, 10(10), e0139446.
[31] He, J., Yan, H., Cai, H., Li, X., Guan, Q., Zheng, W., Chen, R., Liu, H., Song, K., Guo, Z. and Wang, X., Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning, J Transl Med, 2017, 15(1), 198.
[32] Pacini, C., Iorio, F., Gonçalves, E., Iskar, M., Klabunde, T., Bork, P. and Saez-Rodriguez, J., DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data, Bioinformatics, 2013, 29(1), 132-134.
[33] Wang, F., Ding, Y., Lei, X., Liao, B. and Wu, F. X., Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine, IEEE J Biomed Health Inform, 2021, 25(11), 4079-4088.
[34] Wang, F., Ding, Y., Lei, X., Liao, B. and Wu, F. X., Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering, IEEE/ACM Trans Comput Biol Bioinform, 2022, 19(2), 953-965.
[35] Zhu, F. X., He, Y. C., Zhang, J. Y., Wang, H. F., Zhong, C. and Wang, X. T., Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma, Med Sci Monit, 2019, 25, 3247-3255.
[36] Bonfiglio, F., Hysi, P. G., Ek, W., Karhunen, V., Rivera, N. V., Männikkö, M., Nordenstedt, H., Zucchelli, M., Bresso, F., Williams, F., Tornblom, H., Magnusson, P. K., Pedersen, N. L., Ronkainen, J., Schmidt, P. T. and D'Amato, M., A meta-analysis of reflux genome-wide association studies in 6750 Northern Europeans from the general population, Neurogastroenterol Motil, 2017, 29(2), .
[37] Park, S., Kim, D., Song, J. and Joo, J. W. J., An Integrative Transcriptome-Wide Analysis of Amyotrophic Lateral Sclerosis for the Identification of Potential Genetic Markers and Drug Candidates, Int J Mol Sci, 2021, 22(6), .
[38] Nisar, H., Wajid, B., Anwar, F., Ahmad, A., Javaid, A., Attique, S. A., Nisar, W., Saeed, A., Shahid, S. and Sadaf, S., Bioinformatics and systems biology analysis revealed PMID26394986-Compound-10 as potential repurposable drug against covid-19, J Biomol Struct Dyn, 2023, 1-14.
[39] Mugiyanto, E., Adikusuma, W., Irham, L. M., Huang, W. C., Chang, W. C. and Kuo, C. N., Integrated genomic analysis to identify druggable targets for pancreatic cancer, Front Oncol, 2022, 12, 989077.
[40] Irham, L. M., Wong, H. S., Chou, W. H., Adikusuma, W., Mugiyanto, E., Huang, W. C. and Chang, W. C., Integration of genetic variants and gene network for drug repurposing in colorectal cancer, Pharmacol Res, 2020, 161, 105203.
[41] Liu, Z., Chen, X., Roberts, R., Huang, R., Mikailov, M. and Tong, W., Unraveling Gene Fusions for Drug Repositioning in High-Risk Neuroblastoma, Front Pharmacol, 2021, 12, 608778.
[42] Zhang, Z., Cao, C., Zhou, C. L., Li, X., Miao, C., Shen, L., Singla, R. K. and Lu, X., Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing, Transl Oncol, 2023, 36, 101741.
[43] Zhou, Y., Xu, J., Hou, Y., Bekris, L., Leverenz, J. B., Pieper, A. A., Cummings, J. and Cheng, F., The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease, Alzheimers Dement (N Y), 2022, 8(1), e12350.
[44] Wang, S., Meng, X., Wang, Y., Liu, Y. and Xia, J., HPO-Shuffle: an associated gene prioritization strategy and its application in drug repurposing for the treatment of canine epilepsy, Biosci Rep, 2019, 39(9), .
[45] Masson, S. W. C., Madsen, S., Cooke, K. C., Potter, M., Vegas, A. D., Carroll, L., Thillainadesan, S., Cutler, H. B., Walder, K. R., Cooney, G. J., Morahan, G., Stöckli, J. and James, D. E., Leveraging genetic diversity to identify small molecules that reverse mouse skeletal muscle insulin resistance, Elife, 2023, 12, .
[46] Wei, G. G., Gao, L., Tang, Z. Y., Lin, P., Liang, L. B., Zeng, J. J., Chen, G. and Zhang, L. C., Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression, Pathol Res Pract, 2019, 215(6), 152378.
[47] Hu, R. Y., Tian, X. B., Li, B., Luo, R., Zhang, B. and Zhao, J. M., Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm, Pharmgenomics Pers Med, 2019, 12, 369-375.
[48] Yu, L., Wang, M., Yang, Y., Xu, F., Zhang, X., Xie, F., Gao, L. and Li, X., Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways, PLoS Comput Biol, 2021, 17(2), e1008696.
[49] Malcomson, B., Wilson, H., Veglia, E., Thillaiyampalam, G., Barsden, R., Donegan, S., El Banna, A., Elborn, J. S., Ennis, M., Kelly, C., Zhang, S. D. and Schock, B. C., Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis, Proc Natl Acad Sci U S A, 2016, 113(26), E3725-3734.
[50] Cheng, F., Murray, J. L., Zhao, J., Sheng, J., Zhao, Z. and Rubin, D. H., Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis, PLoS Comput Biol, 2016, 12(9), e1005074.
[51] Han, L., Li, K., Jin, C., Wang, J., Li, Q., Zhang, Q., Cheng, Q., Yang, J., Bo, X. and Wang, S., Human enterovirus 71 protein interaction network prompts antiviral drug repositioning, Sci Rep, 2017, 7, 43143.
[52] Yang, X., Huang, W. T., Wu, H. Y., He, R. Q., Ma, J., Liu, A. G. and Chen, G., Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing, Oncol Rep, 2019, 41(4), 2241-2253.
[53] Yu, W. Y., Hill, S. T., Chan, E. R., Pink, J. J., Cooper, K., Leachman, S., Lund, A. W., Kulkarni, R. and Bordeaux, J. S., Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma, J Invest Dermatol, 2021, 141(7), 1802-1809.
[54] Coria-Rodríguez, H., Ochoa, S., de Anda-Jáuregui, G. and Hernández-Lemus, E., Drug repurposing for Basal breast cancer subpopulations using modular network signatures, Comput Biol Chem, 2023, 105, 107902.
[55] Cheng, Y., Hou, K., Wang, Y., Chen, Y., Zheng, X., Qi, J., Yang, B., Tang, S., Han, X., Shi, D., Wang, X., Liu, Y., Hu, X. and Che, X., Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma, Front Oncol, 2021, 11, 665276.
[56] Song, J., Kim, D., Lee, S., Jung, J., Joo, J. W. J. and Jang, W., Integrative transcriptome-wide analysis of atopic dermatitis for drug repositioning, Commun Biol, 2022, 5(1), 615.
[57] Wei, Z., Zhu, S., Chen, X., Zhu, C., Duan, B. and Liu, Q., DrSim: Similarity Learning for Transcriptional Phenotypic Drug Discovery, Genomics Proteomics Bioinformatics, 2022, 20(5), 1028-1036.
[58] Wang, X., He, S., Zhou, Z., Bo, X., Qi, D., Fu, X., Wang, Z., Yang, J. and Wang, S., LINCS dataset-based repositioning of rosiglitazone as a potential anti-human adenovirus drug, Antiviral Res, 2020, 179, 104789.
[59] So, H. C., Chau, C. K., Chiu, W. T., Ho, K. S., Lo, C. P., Yim, S. H. and Sham, P. C., Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry, Nat Neurosci, 2017, 20(10), 1342-1349.
[60] Connolly, R. M., Rudek, M. A., Garrett-Mayer, E., Jeter, S. C., Donehower, M. G., Wright, L. A., Zhao, M., Fetting, J. H., Emens, L. A., Stearns, V., Davidson, N. E., Baker, S. D. and Wolff, A. C., Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer, Breast Cancer Res Treat, 2011, 127(1), 153-162.
[61] Chew, H. K., Barlow, W. E., Albain, K., Lew, D., Gown, A., Hayes, D. F., Gralow, J., Hortobagyi, G. N. and Livingston, R., A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338, Clin Breast Cancer, 2008, 8(6), 511-515.
[62] Yardley, D. A., Burris, H. A., 3rd, Markus, T., Spigel, D. R., Greco, F. A., Mainwaring, M., Waterhouse, D. M., Webb, C. D. and Hainsworth, J. D., Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer, Clin Breast Cancer, 2009, 9(4), 237-242.
[63] Maass, N., Schem, C., Bauerschlag, D. O., Tiemann, K., Schaefer, F. W., Hanson, S., Muth, M., Baier, M., Weigel, M. T., Wenners, A. S., Alkatout, I., Bauer, M., Jonat, W. and Mundhenke, C., Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer, Oncology, 2014, 87(5), 300-310.
[64] Oskolkova, M. K., Vul'fson, I. N., Shiriaeva, I. S. and Krasina, G. A., [On the problem of sinus arrhythmia in children], Sov Med, 1967, 30(4), 73-76.
[65] Muir, D. C., Bernholz, C. D., Morgan, W. K., Roos, J. O., Chan, J., Maehle, W., Julian, J. A. and Sebestyen, A., Classification of chest radiographs for pneumoconiosis: a comparison of two methods of reading, Br J Ind Med, 1992, 49(12), 869-871.
[66] Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D. W., Anderson, D. M., Stella, P. J., Niedringhaus, R., Bernath, A. M., Gamini, S. S., Palmieri, F. and Perez, E. A., N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial, Ann Oncol, 2010, 21(3), 493-497.
[67] O'Connor, T., Rustum, Y., Levine, E. and Creaven, P., A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer, Cancer Chemother Pharmacol, 2008, 61(1), 125-131.
[68] Argiris, A., Buchanan, A., Brockstein, B., Kolesar, J., Ghebremichael, M., Pins, M., Hahn, K., Axelrod, R. and Forastiere, A., Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group, Cancer, 2009, 115(19), 4504-4513.
[69] Gilbert, J., Cmelak, A., Shyr, Y., Netterville, J., Burkey, B. B., Sinard, R. J., Yarbrough, W. G., Chung, C. H., Aulino, J. M. and Murphy, B. A., Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck, Cancer, 2008, 113(1), 186-192.
[70] Gilbert, J., Li, Y., Pinto, H. A., Jennings, T., Kies, M. S., Silverman, P. and Forastiere, A. A., Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group, Head Neck, 2006, 28(3), 197-204.
[71] Amrein, P. C., Clark, J. R., Supko, J. G., Fabian, R. L., Wang, C. C., Colevas, A. D., Posner, M. R., Deschler, D. G., Rocco, J. W., Finkelstein, D. M. and McIntyre, J. F., Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma, Cancer, 2005, 104(7), 1418-1427.
[72] Langer, C. J., Harris, J., Horwitz, E. M., Nicolaou, N., Kies, M., Curran, W., Wong, S. and Ang, K., Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911, J Clin Oncol, 2007, 25(30), 4800-4805.
[73] Rosenthal, D. I., Harris, J., Forastiere, A. A., Weber, R. S., Ridge, J. A., Myers, J. N., Garden, A. S., Kuettel, M. R., Sidhu, K., Schultz, C. J., Trotti, A. and Ang, K. K., Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024, J Clin Oncol, 2009, 27(28), 4727-4732.
[74] Cmelak, A. J., Li, S., Goldwasser, M. A., Murphy, B., Cannon, M., Pinto, H., Rosenthal, D. I., Gillison, M. and Forastiere, A. A., Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399, J Clin Oncol, 2007, 25(25), 3971-3977.
[75] Haddad, R., Sonis, S., Posner, M., Wirth, L., Costello, R., Braschayko, P., Allen, A., Mahadevan, A., Flynn, J., Burke, E., Li, Y. and Tishler, R. B., Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer, Cancer, 2009, 115(19), 4514-4523.
[76] Kies, M. S., Holsinger, F. C., Lee, J. J., William, W. N., Jr., Glisson, B. S., Lin, H. Y., Lewin, J. S., Ginsberg, L. E., Gillaspy, K. A., Massarelli, E., Byers, L., Lippman, S. M., Hong, W. K., El-Naggar, A. K., Garden, A. S. and Papadimitrakopoulou, V., Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial, J Clin Oncol, 2010, 28(1), 8-14.
[77] Hainsworth, J. D., Spigel, D. R., Greco, F. A., Shipley, D. L., Peyton, J., Rubin, M., Stipanov, M. and Meluch, A., Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium, Cancer J, 2011, 17(5), 267-272.
[78] Langer, C. J., Li, Y., Jennings, T., DeConti, R. C., Nair, S., Cohen, R. B. and Forastiere, A. A., Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group, Cancer Invest, 2004, 22(6), 823-831.
[79] Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H., DeConti, R. C., Ensley, J. and Forastiere, A. A., Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 2005, 23(15), 3562-3567.
[80] Worden, F. P., Moon, J., Samlowski, W., Clark, J. I., Dakhil, S. R., Williamson, S., Urba, S. G., Ensley, J. and Hussain, M. H., A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007, Cancer, 2006, 107(2), 319-327.
[81] Koeberle, D., Dufour, J. F., Demeter, G., Li, Q., Ribi, K., Samaras, P., Saletti, P., Roth, A. D., Horber, D., Buehlmann, M., Wagner, A. D., Montemurro, M., Lakatos, G., Feilchenfeldt, J., Peck-Radosavljevic, M., Rauch, D., Tschanz, B. and Bodoky, G., Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29), Ann Oncol, 2016, 27(5), 856-861.
[82] Alberts, S. R., Reid, J. M., Morlan, B. W., Farr, G. H., Jr., Camoriano, J. K., Johnson, D. B., Enger, J. R., Seay, T. E. and Kim, G. P., Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial, Am J Clin Oncol, 2012, 35(5), 418-423.
[83] Louafi, S., Boige, V., Ducreux, M., Bonyhay, L., Mansourbakht, T., de Baere, T., Asnacios, A., Hannoun, L., Poynard, T. and Taïeb, J., Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study, Cancer, 2007, 109(7), 1384-1390.
[84] Lombardi, G., Zustovich, F., Farinati, F., Cillo, U., Vitale, A., Zanus, G., Donach, M., Farina, M., Zovato, S. and Pastorelli, D., Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study, Cancer, 2011, 117(1), 125-133.
[85] Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B., de Camargo, B., Zsiros, J., Roebuck, D., Zimmermann, A., Aronson, D., Childs, M., Widing, E., Laithier, V., Plaschkes, J., Pritchard, J., Scopinaro, M., MacKinlay, G. and Czauderna, P., Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma, N Engl J Med, 2009, 361(17), 1662-1670.
[86] Knox, J. J., Chen, X. E., Feld, R., Nematollahi, M., Cheiken, R., Pond, G., Zwiebel, J. A., Gill, S. and Moore, M., A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798), Invest New Drugs, 2008, 26(2), 193-194.
[87] Gish, R. G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A., Feun, L., Jeziorski, K., Leighton, J., Gallo, J. and Kennealey, G. T., Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol, 2007, 25(21), 3069-3075.
[88] Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., Leung, T., Gansukh, B. and Saltz, L. B., Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial, Jama, 2010, 304(19), 2154-2160.
[89] Reyes, D. K., Vossen, J. A., Kamel, I. R., Azad, N. S., Wahlin, T. A., Torbenson, M. S., Choti, M. A. and Geschwind, J. F., Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States, Cancer J, 2009, 15(6), 526-532.
[90] Dufour, J. F., Hoppe, H., Heim, M. H., Helbling, B., Maurhofer, O., Szucs-Farkas, Z., Kickuth, R., Borner, M., Candinas, D. and Saar, B., Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study, Oncologist, 2010, 15(11), 1198-1204.
[91] Salem, R., Gordon, A. C., Mouli, S., Hickey, R., Kallini, J., Gabr, A., Mulcahy, M. F., Baker, T., Abecassis, M., Miller, F. H., Yaghmai, V., Sato, K., Desai, K., Thornburg, B., Benson, A. B., Rademaker, A., Ganger, D., Kulik, L. and Lewandowski, R. J., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, 2016, 151(6), 1155-1163.e1152.
[92] Roswarski, J., Roschewski, M., Lucas, A., Melani, C., Pittaluga, S., Jaffe, E. S., Steinberg, S. M., Waldmann, T. A. and Wilson, W. H., Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas, Leuk Lymphoma, 2018, 59(6), 1466-1469.
[93] Chiorean, E. G., Ramasubbaiah, R., Yu, M., Picus, J., Bufill, J. A., Tong, Y., Coleman, N., Johnston, E. L., Currie, C. and Loehrer, P. J., Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101, Oncologist, 2012, 17(1), 13.
[94] Knox, J. J., Gill, S., Synold, T. W., Biagi, J. J., Major, P., Feld, R., Cripps, C., Wainman, N., Eisenhauer, E. and Seymour, L., A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168), Invest New Drugs, 2008, 26(3), 265-272.
[95] Guiu, B., Chevallier, P., Assenat, E., Barbier, E., Merle, P., Bouvier, A., Dumortier, J., Nguyen-Khac, E., Gugenheim, J., Rode, A., Oberti, F., Valette, P. J., Yzet, T., Chevallier, O., Barbare, J. C., Latournerie, M. and Boulin, M., Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial, Radiology, 2019, 291(3), 801-808.
[96] Yau, T., Chen, P. J., Chan, P., Curtis, C. M., Murphy, P. S., Suttle, A. B., Gauvin, J., Hodge, J. P., Dar, M. M. and Poon, R. T., Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics, Clin Cancer Res, 2011, 17(21), 6914-6923.
[97] Safran, H., Charpentier, K. P., Kaubisch, A., Mantripragada, K., Dubel, G., Perez, K., Faricy-Anderson, K., Miner, T., Eng, Y., Victor, J., Plette, A., Espat, J., Bakalarski, P., Wingate, P., Berz, D., Luppe, D., Martel, D., Rosati, K. and Aparo, S., Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study, Am J Clin Oncol, 2015, 38(1), 1-4.
[98] Chow, P. K., Machin, D., Chen, Y., Zhang, X., Win, K. M., Hoang, H. H., Nguyen, B. D., Jin, M. Y., Lobo, R., Findlay, M., Lim, C. H., Tan, S. B., Gandhi, M. and Soo, K. C., Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma, Br J Cancer, 2011, 105(7), 945-952.
[99] Price, K. A., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E. and Miller, V. A., Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer, J Thorac Oncol, 2010, 5(10), 1623-1629.
[100] Gandhi, L., Harding, M. W., Neubauer, M., Langer, C. J., Moore, M., Ross, H. J., Johnson, B. E. and Lynch, T. J., A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer, Cancer, 2007, 109(5), 924-932.
[101] Fenwick, D., The nurse who came in from the cold, Aust Nurses J, 1982, 11(10), 47-50.
[102] Thatcher, N., Qian, W., Clark, P. I., Hopwood, P., Sambrook, R. J., Owens, R., Stephens, R. J. and Girling, D. J., Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial, J Clin Oncol, 2005, 23(33), 8371-8379.
[103] Johnson, M. L., Riely, G. J., Rizvi, N. A., Azzoli, C. G., Kris, M. G., Sima, C. S., Ginsberg, M. S., Pao, W. and Miller, V. A., Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib, J Thorac Oncol, 2011, 6(6), 1128-1131.
[104] Brunner, A. M., Costa, D. B., Heist, R. S., Garcia, E., Lindeman, N. I., Sholl, L. M., Oxnard, G. R., Johnson, B. E. and Hammerman, P. S., Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung, J Thorac Oncol, 2013, 8(11), 1434-1437.
[105] Horinouchi, H., Yamamoto, N., Nokihara, H., Horai, T., Nishio, M., Ohyanagi, F., Horiike, A., Nakagawa, K., Terashima, M., Okabe, T., Kaneda, H., McKee, M. D., Carlson, D. M., Xiong, H. and Tamura, T., A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC), Cancer Chemother Pharmacol, 2014, 74(1), 37-43.
[106] Rinehart, J., Arnold, S., Kloecker, G., Lim, A., Zaydan, M. A., Baeker, T., Maheshwari, J. G., Carloss, H., Slone, S., Shelton, B., Croley, J., Kvale, E., Brooks, M. and Leggas, M., Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer, Cancer Chemother Pharmacol, 2013, 71(5), 1375-1383.
[107] Kharofa, J., Cohen, E. P., Tomic, R., Xiang, Q. and Gore, E., Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy, Int J Radiat Oncol Biol Phys, 2012, 84(1), 238-243.
[108] Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., Lee, B., Tsai, S., Delgado, I. E., Rudek, M. A., Belinsky, S. A., Herman, J. G., Baylin, S. B., Brock, M. V. and Rudin, C. M., Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, 2011, 1(7), 598-607.
[109] Keith, R. L., Blatchford, P. J., Kittelson, J., Minna, J. D., Kelly, K., Massion, P. P., Franklin, W. A., Mao, J., Wilson, D. O., Merrick, D. T., Hirsch, F. R., Kennedy, T. C., Bunn, P. A., Jr., Geraci, M. W. and Miller, Y. E., Oral iloprost improves endobronchial dysplasia in former smokers, Cancer Prev Res (Phila), 2011, 4(6), 793-802.
[110] Nechushtan, H., Hamamreh, Y., Nidal, S., Gotfried, M., Baron, A., Shalev, Y. I., Nisman, B., Peretz, T. and Peylan-Ramu, N., A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer, Oncologist, 2015, 20(4), 366-367.
[111] Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., Sherman, S. I., Smit, J. W., Chung, J., Kappeler, C., Peña, C., Molnár, I. and Schlumberger, M. J., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 2014, 384(9940), 319-328.
[112] Worden, F., Fassnacht, M., Shi, Y., Hadjieva, T., Bonichon, F., Gao, M., Fugazzola, L., Ando, Y., Hasegawa, Y., Park, D. J., Shong, Y. K., Smit, J. W., Chung, J., Kappeler, C., Meinhardt, G., Schlumberger, M. and Brose, M. S., Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer, Endocr Relat Cancer, 2015, 22(6), 877-887.
[113] Hayes, D. N., Lucas, A. S., Tanvetyanon, T., Krzyzanowska, M. K., Chung, C. H., Murphy, B. A., Gilbert, J., Mehra, R., Moore, D. T., Sheikh, A., Hoskins, J., Hayward, M. C., Zhao, N., O'Connor, W., Weck, K. E., Cohen, R. B. and Cohen, E. E., Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements, Clin Cancer Res, 2012, 18(7), 2056-2065.
[114] Pantziarka, P., Capistrano, I. R., De Potter, A., Vandeborne, L. and Bouche, G., An Open Access Database of Licensed Cancer Drugs, Front Pharmacol, 2021, 12, 627574.
[115] Pantziarka, P., Vandeborne, L. and Bouche, G., A Database of Drug Repurposing Clinical Trials in Oncology, Front Pharmacol, 2021, 12, 790952.
[116] Yang, L., Li, A., Wang, Y. and Zhang, Y., Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy, Signal Transduct Target Ther, 2023, 8(1), 35.
[117] Zhang, Z., Liao, Y. and Tang, D., Intratumoral microbiota: new frontiers in tumor immunity, Carcinogenesis, 2022, 43(8), 719-727.
[118] Xie, Y., Xie, F., Zhou, X., Zhang, L., Yang, B., Huang, J., Wang, F., Yan, H., Zeng, L., Zhang, L. and Zhou, F., Microbiota in Tumors: From Understanding to Application, Adv Sci (Weinh), 2022, 9(21), e2200470.
[119] Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., Wang, C., Guo, Y., Li, N. and Cai, S., Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer, Cell, 2022, 185(8), 1356-1372.e1326.
[120] Fu, A., Yao, B., Dong, T. and Cai, S., Emerging roles of intratumor microbiota in cancer metastasis, Trends Cell Biol, 2023, 33(7), 583-593.
[121] Parkkinen, J. A. and Kaski, S., Probabilistic drug connectivity mapping, BMC Bioinformatics, 2014, 15, 113.
[122] Liu, L., Tsompana, M., Wang, Y., Wu, D., Zhu, L. and Zhu, R., Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis, J Chem Inf Model, 2016, 56(9), 1615-1621.
[123] Jin, L., Tu, J., Jia, J., An, W., Tan, H., Cui, Q. and Li, Z., Drug-repurposing identified the combination of Trolox C and Cytisine for the treatment of type 2 diabetes, J Transl Med, 2014, 12, 153.